KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Non Operating Investment Income (2016 - 2017)

Historic Non Operating Investment Income for Supernus Pharmaceuticals (SUPN) over the last 6 years, with Q2 2017 value amounting to $23000.0.

  • Supernus Pharmaceuticals' Non Operating Investment Income fell 8130.08% to $23000.0 in Q2 2017 from the same period last year, while for Dec 2017 it was $77000.0, marking a year-over-year decrease of 8281.25%. This contributed to the annual value of $76000.0 for FY2017, which is 8303.57% down from last year.
  • Supernus Pharmaceuticals' Non Operating Investment Income amounted to $23000.0 in Q2 2017, which was down 8130.08% from $54000.0 recorded in Q1 2017.
  • Supernus Pharmaceuticals' Non Operating Investment Income's 5-year high stood at $760000.0 during Q3 2014, with a 5-year trough of -$8.6 million in Q2 2013.
  • In the last 5 years, Supernus Pharmaceuticals' Non Operating Investment Income had a median value of $100000.0 in 2016 and averaged -$545944.4.
  • In the last 5 years, Supernus Pharmaceuticals' Non Operating Investment Income tumbled by 588541.67% in 2013 and then skyrocketed by 1220000.0% in 2016.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' Non Operating Investment Income stood at -$662000.0 in 2013, then surged by 204.83% to $694000.0 in 2014, then plummeted by 81.7% to $127000.0 in 2015, then fell by 22.05% to $99000.0 in 2016, then plummeted by 76.77% to $23000.0 in 2017.
  • Its Non Operating Investment Income was $23000.0 in Q2 2017, compared to $54000.0 in Q1 2017 and $99000.0 in Q4 2016.